miR-19a和miR-19b在骨肉瘤中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2017.01.011

癌变·畸变·突变 ›› 2017, Vol. 29 ›› Issue (1): 55-59.doi: 10.3969/j.issn.1004-616x.2017.01.011

miR-19a和miR-19b在骨肉瘤中的表达及其临床意义

胡维信¹, 赵智伟²

1. 开封市中心医院骨二科, 河南开封 475000;
2. 河南科技大学第一附属医院康复科, 河南开封 475000

收稿日期:2016-09-08 修回日期:2016-12-05 出版日期:2017-01-31 发布日期:2017-01-31
通讯作者: 赵智伟,E-mail:1980zhaozhiwei@sina.com E-mail:1980zhaozhiwei@sina.com
作者简介:胡维信,E-mail:hwx2010@126.com

Expression of miR-19a and miR-19b and their clinical significance in osteosarcoma

HU Weixin¹, ZHAO Zhiwei²

1. Orthopedics Department II Ward, Kaifeng Central Hospital, Kaifeng 475000;
2. Physiatry Department, the First Affilliated Hospital of Henan University of Science and Technology, Kaifeng 475000, Henan, China

Received:2016-09-08 Revised:2016-12-05 Online:2017-01-31 Published:2017-01-31

摘要/Abstract

摘要：

目的：探讨miR-19a和miR-19b在骨肉瘤组织及配对瘤旁组织中的表达及其与临床病理特征的相关性。方法：收集32对骨肉瘤和配对的瘤旁组织，运用实时荧光定量PCR（qPCR）检测骨肉瘤组织及其瘤旁组织中miR-19a和miR-19b的表达，分析其与骨肉瘤临床病理特征的相关性及其临床意义。结果：qPCR结果显示骨肉瘤组织中miR-19a和miR-19b的平均表达量较瘤旁组织中均明显上调（P均 < 0.05）。二者的表达水平呈正相关（r=0.685，P=0.000）。miR-19a和miR-19b的表达与骨肉瘤病理分级之间存在正相关（r=0.478，P=0.027）；miR-19a的表达与临床分期呈正相关（r=0.365，P=0.031）且与预后相关。Cox回归多因素分析发现miR-19a可作为骨肉瘤患者预后的影响因子（P=0.037）。结论：miR-19a和miR-19b在骨肉瘤中表达上调，在骨肉瘤的发生发展中可能发挥重要的作用，其中miR-19a可能作为骨肉瘤独立的预后标志物。

关键词: 骨肉瘤, miR-19a, miR-19b, 预后

Abstract:

OBJECTIVE: To investigate the expression of miR-19a and miR-19b in osteosarcoma and adjacent non-cancerous tissues,and their correlation with clinicopathologic characteristics. METHODS: 32 cases of osteosar-coma tissues and paired adjacent non-cancerous tissues were collected. qPCR was used to detect the expressions of miR-19a and miR-19b in the two tissues. Correlation between expression of the miRNA and clinical pathologic changes was performed. RESULTS: Expression of miR-19a and miR-19b was significantly up-regulated in osteosarcoma tissues as compared with the adjacent non-cancerous tissues. Their expression nucleic acid levels was positively and significantly correlated with pathologic gradings (all P < 0.05). The expression of the miR-19a was also positive correlated with clinical stage of osteosarcoma and related to the prognosis (r=0.685,P < 0.05). Multivariate analyses suggested that miR-19a expression was an independent predictor for overall survival (P=0.037). CONCLUSION: Our study showed that miR-19a and miR-19b may play an important role in the tumorigenesis and progression of osteosarcoma. In particular,miR-19a may serve as a prognostic marker and therapeutic target for osteosacoma.

Key words: osteosarcoma, miR-19a, miR-19b, prognosis

中图分类号:

R711.74

胡维信, 赵智伟. miR-19a和miR-19b在骨肉瘤中的表达及其临床意义[J]. 癌变·畸变·突变, 2017, 29(1): 55-59.

HU Weixin, ZHAO Zhiwei. Expression of miR-19a and miR-19b and their clinical significance in osteosarcoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 55-59.

参考文献

[1] NUGENT M. microRNA and bone cancer[J]. Adv Exp Med Biol,2015,889:201-230.

[2] KAFCHINSKI L A,JONES K B. MicroRNAs in osteosar-comagenesis[J]. Adv Exp Med Biol,2014,804:119-127.

[3] ALLEN-RHOADES W,KURENBEKOVA L,SATTERFIELD L,et al. Cross-species identification of a plasma microRNA signature for detection,therapeutic monitoring,and prognosis in osteosarcoma[J]. Cancer Med,2015,4(7):977-988.

[4] ZIYAN W,SHUHUA Y,XIUFANG W,et al. MicroRNA-21 is involved in osteosarcoma cell invasion and migration[J]. Med Oncol,2011,28(4):1469-1474.

[5] TSUCHIDA A,OHNO S,WU W,et al. miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer[J]. Cancer Sci,2011,102(12):2264-2271.

[6] MENDELL J T. miRiad roles for the miR-17-92 cluster in development and disease[J]. Cell,2008,133(2):217-222.

[7] HE L,THOMSON J M,HEMANN M T,et al. A microRNA polycistron as a potential human oncogene[J]. Nature,2005, 435(7043):828-833.

[8] WU W,TAKANASHI M,BORJIGIN N,et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis[J]. Br J Cancer, 2013,108(3):653-661.

[9] MATSUBARA H,TAKEUCHI T,NISHIKAWA E,et al. Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92[J]. Oncogene,2007,26(41):6099-6105.

[10] MORIMURA R,KOMATSU S,ICHIKAWA D,et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer[J]. Br J Cancer,2011,105(11):1733-1740.

[11] HUANG G,NISHIMOTO K,YANG Y,et al. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases[J]. Adv Exp Med Biol,2014,804:203-217.

[12] ZHU H,HAN C,LU D,et al. miR-17-92 cluster promotes cholangiocarcinoma growth:evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator[J]. Am J Pathol, 2014,184(10):2828-2839.

[13] WANG F,LI T,ZHANG B,et al. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN[J]. Biochem Biophys Res Commun,2013,434(3):688-694.

[14] XU X L,JIANG Y H,FENG J G,et al. MicroRNA-17, microRNA-18a,and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma[J]. Ann Thorac Surg, 2014,97(3):1037-1045.

[1]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[2]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[3]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[4]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.
[5]	张世民, 赵瑞君. 蛋白酪氨酸磷酸酶受体J在乳腺癌组织中的表达及其与临床预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 276-279,285.
[6]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[7]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[8]	李玮玮, 朱莹. 数据挖掘分析MYB家族在乳腺癌中的表达及其预后评估价值[J]. 癌变·畸变·突变, 2020, 32(6): 414-422.
[9]	石海林, 何天基, 刘峰, 蔡孟会, 葛波. 基于TCGA数据库分析肿瘤突变负荷在肌层浸润性膀胱癌预后评估中的价值[J]. 癌变·畸变·突变, 2020, 32(6): 430-437,443.
[10]	丁雅雯, 焦文静, 王芃堉, 鹿刚, 马鸣. 多发性骨髓瘤患者浆细胞免疫表型特点及其临床意义研究[J]. 癌变·畸变·突变, 2020, 32(6): 464-468,489.
[11]	黎梓蕊, 许键, 李红文, 张鹏. 口腔癌相关microRNA的研究进展[J]. 癌变·畸变·突变, 2020, 32(6): 481-484.
[12]	邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.
[13]	吕燕萍, 吴传城, 杨双凤, 何陈周, 韩仁杰, 颜伟, 刘宝英. 胃癌差异表达miRNA及其相关基因的单核苷酸多态性与胃癌预后的相关性研究[J]. 癌变·畸变·突变, 2020, 32(5): 380-386.
[14]	郭秀娟, 杜彦艳, 颜晰, 赵学涛, 韩丽娜, 武一鹏, 王雪晓, 马鸣. CREB在食管鳞癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 387-390,394.
[15]	朱依青, 张彤彤, 郑珺文, 郝佳洁, 蔡岩, 王明荣, 梁建伟, 张钰. p-mTOR蛋白在结直肠癌组织中的表达及患者预后判断中的价值[J]. 癌变·畸变·突变, 2020, 32(3): 161-165.

miR-19a和miR-19b在骨肉瘤中的表达及其临床意义

Expression of miR-19a and miR-19b and their clinical significance in osteosarcoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价